
### [NCIT:C4032](http://purl.obolibrary.org/obo/NCIT_C4032)
**Label:** Bladder Adenocarcinoma

**Subclasses:** [NCIT:C4995](http://purl.obolibrary.org/obo/NCIT_C4995) (Recurrent Bladder Adenocarcinoma), [NCIT:C8898](http://purl.obolibrary.org/obo/NCIT_C8898) (Stage IV Bladder Adenocarcinoma), [NCIT:C8896](http://purl.obolibrary.org/obo/NCIT_C8896) (Stage II Bladder Adenocarcinoma), [NCIT:C8897](http://purl.obolibrary.org/obo/NCIT_C8897) (Stage III Bladder Adenocarcinoma), [NCIT:C8894](http://purl.obolibrary.org/obo/NCIT_C8894) (Stage 0 Bladder Adenocarcinoma), [NCIT:C8895](http://purl.obolibrary.org/obo/NCIT_C8895) (Stage I Bladder Adenocarcinoma), 

**Class expressions from DL-Learner:**

- [NCIT:C39875](http://purl.obolibrary.org/obo/NCIT_C39875) (Loss of Chromosome 9q) 58.33%
- [NCIT:C36636](http://purl.obolibrary.org/obo/NCIT_C36636) (Loss of Chromosome 9p) 58.33%
- [NCIT:C36505](http://purl.obolibrary.org/obo/NCIT_C36505) (Loss of Chromosome 11p) 58.33%
- [NCIT:C36503](http://purl.obolibrary.org/obo/NCIT_C36503) (Loss of Chromosome 8p) 58.33%
- [NCIT:C36499](http://purl.obolibrary.org/obo/NCIT_C36499) (Loss of Chromosome 17p) 58.33%
- [NCIT:C2999](http://purl.obolibrary.org/obo/NCIT_C2999) (Dysuria) 58.33%
- [NCIT:C36315](http://purl.obolibrary.org/obo/NCIT_C36315) (Chromosomal Loss) 57.64%
- Thing 51.99%
- [NCIT:C6825](http://purl.obolibrary.org/obo/NCIT_C6825) (Numerical Chromosomal Abnormality) 50.98%
- [NCIT:C2950](http://purl.obolibrary.org/obo/NCIT_C2950) (Cytogenetic Abnormality) 48.10%
- [NCIT:C3910](http://purl.obolibrary.org/obo/NCIT_C3910) (Molecular Abnormality) 46.62%
- [NCIT:C36286](http://purl.obolibrary.org/obo/NCIT_C36286) (Urinary System Finding) 33.33%
- [NCIT:C5035](http://purl.obolibrary.org/obo/NCIT_C5035) (Genitourinary Signs and Symptoms) 27.23%
- [NCIT:C100104](http://purl.obolibrary.org/obo/NCIT_C100104) (Sign or Symptom) 14.19%
- [NCIT:C36278](http://purl.obolibrary.org/obo/NCIT_C36278) (Finding by Site or System) 12.36%


